Skip to content

Potential New Treatment for Alpha-1 Antitrypsin Deficiency

Search Clinical Trials

Trial Objectives


Researchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.

Who Can Participate


People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate.

Age: 18-80 Gender Any

Estimated Time Commitment


Not Specified

Payment & Reimbursement


Payment Provided

Travel Reimbursement Available

Trial Contact


For more information, contact:

Kristina Eliopoulos
303.270.2622

Request More Information

Trial Location


National Jewish Main Campus, Denver, CO

Trial Sponsors


National Institutes of Health, University of Alabama at Birmingham

Principal Investigators

Robert A. Sandhaus

Robert A. Sandhaus, MD, PhD, FCCP

Co-Investigators

Karina A. Serban

Karina A. Serban, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required